What are the highlights of the global collection of clinical advances in RNAi drugs that are worth looking forward to?

RNAi therapy can potentially be applied to a variety of diseases with long active duration in the human body.

Source: Public information of Shengnuo Pharmaceutical

A new chapter in cancer treatment may open

There are 4 RNAi drugs that have been approved for marketing in the world.

Among the main clinical RNAi drugs in the world, there are 4 oncology drugs, among which Sirnaomics' STP705 is the most concerned.

Image source: Shengnuo Pharmaceutical

Although RNAi therapy in oncology is in the early stage, and the representative drug STP705 is also in the phase II clinical stage, RNAi therapy can effectively inhibit the growth of advanced tumors in cancer treatment, with relatively low cost and high specificity.

The era of rare diseases is coming

Among the major clinical RNAi drugs in the world, as many as 9 are used to treat rare diseases, which are the main disease direction of RNAi clinical trials.

Alnylam’s Fitusiran (ALN-AT3) is used for the treatment of hemophilia A and B.

Arrowhead’s ARO-APOC3 is used for the treatment of familial chylomicronemia, and has obtained the U.

In addition, there are a number of clinical drugs that have been certified by the US FDA orphan drug, such as ARO-AAT, ARO-AGN3 and Vutrisiran

Among the more than 7,000 rare diseases known in the world, less than 5% of rare diseases have effective treatments.

Can domestic pharmaceutical companies have a place?

The world's first RNAi drug ONPATTRO (Patisiran) was approved for marketing in 2018, with sales of US$166 million and US$306 million in 2019 and 2020, respectively, and US$336 million in the first three quarters of 2021.

Image source: Shengnuo Pharmaceutical

In the field of RNAi therapy, although the main participants are foreign pharmaceutical companies, especially the pharmaceutical company Alnylam, the four RNAi drugs that have been marketed are all developed by this company, but Sirnaomics has two products that are listed in the main clinical drugs.

Image source: Shengnuo Pharmaceutical

In addition to STP705 and STP707, Sirnaomics has a wealth of pipeline products, as well as a globally unique peptide nanointroduction system (PNP) and a new GalNAc RNAi delivery platform

In addition, domestic pharmaceutical companies that also focus on small nucleic acid drugs include Ruibo Biology.

Reference materials:

(1) Prospectus of Shengnuo Pharmaceutical

(2) Official websites of relevant pharmaceutical companies

(3) Other public information